KISQALI (ribociclib) is used for the treatment of patients with breast cancer.

KISQALI is a kinase inhibitor indicated in combination with (1) an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or (2) fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrinebased therapy or following disease progression on endocrine therapy.

KISQALI (ribociclib) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KISQALI (ribociclib) brand in India, sold by indian drug manufacturer. Please call at +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the medicine and its cost price in India.

The order for KISQALI (ribociclib) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals. Ribociclib was approved by the US FDA in March 2017 and the European Medicines Agency in August 2017 for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers.

KISQALI® (ribociclib) tablets, for oral use. Initial U.S. Approval: 2017

Generic Name: ribociclib

Kisqali (ribociclib)

KISQALI® (ribociclib) tablets, for oral use is available.

Get In Touch

KISQALI (ribociclib) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KISQALI (ribociclib) on prescription and Import License in Patient's Name only.

For overseas patients, KISQALI (ribociclib) can be made available in Send your enquiry to find KISQALI (ribociclib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for KISQALI (ribociclib).

For KISQALI (ribociclib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium (SMC) for the treatment of patients with the most common form of advanced breast cancer For More Details

Trial drug shows promise for metastatic breast cancer patients For More Details